CraniUS Therapeutics Awarded Maryland Tech Council's "2025 Emerging Life Sciences Company of the Year"
BALTIMORE, May 29, 2025 /PRNewswire/ — CraniUS Therapeutics, a cutting-edge medical device company advancing intracranial drug delivery, is proud to announce it has been voted the '2025 Emerging Life Sciences Company of the Year' by the Maryland Tech Council (MTC). The honor was presented during the Council's prestigious Industry Awards Celebration, which drew over 600 attendees, and recognizes the state's most innovative and impactful companies in technology and life sciences.
The company's Founder and Executive Chairman, Dr. Chad Gordon, is a leader in Neuroplastic and Reconstructive Surgery. He serves as Section Chief and Fellowship Program Director at Johns Hopkins School of Medicine. Over his career, Dr. Gordon has secured 21 patents, led three successful venture exits, and conducted three first-in-human studies evaluating advanced cranial implants. His invention of the NeuroPASS™ device—CraniUS's core innovation—sparked the company's formation.
This award acknowledges CraniUS's leadership and its groundbreaking development of the NeuroPASS™ platform, which enables direct, reliable delivery of therapeutics to the brain—addressing one of the most persistent challenges in treating brain tumors and other neurological conditions.
'We are honored to be recognized by the Maryland Tech Council with this year's Emerging Company Award,' said Dr. Gordon. 'This milestone reflects not only the dedication of our entire team but also the urgent need for transformative solutions in neurotherapeutics. We are extremely proud to be pioneering the new field of functional neurocranial implants inspired by Neuroplastic Surgery and driving this critical work forward—from right here in Maryland.'
Mike Maglin, CEO of CraniUS Therapeutics, added, 'This award is a testament to the meaningful progress we've made and the momentum we've built—spanning scientific innovation, strategic alliances, and investor engagement. We remain committed to redefining how patients with neurological diseases receive life-changing medicines.'
The Industry Awards Celebration is Maryland's premier event honoring excellence in technology, life sciences, and innovation. CraniUS was selected from a competitive field of nominees for its rapid growth, strong leadership, and the promise of its revolutionary device platform—employing patented neurotechnology—designed to reshape treatment approaches for conditions such as neurodegenerative diseases, movement disorders, and aggressive brain cancers.
About CraniUS TherapeuticsCraniUS Therapeutics is a neurotechnology company developing the first fully implantable platform to bypass the blood-brain barrier for long-term, programmable drug delivery. Its flagship device, NeuroPASS™, is designed to transform the treatment landscape for debilitating neurological conditions across multiple disease types. CraniUS Therapeutics is headquartered in Baltimore, Maryland, and collaborates globally with industry leading experts in neurosurgery, drug delivery, implant design, device engineering, and manufacturing.
Media Contact:Elizabeth A. Dale, EdDExecutive Advisor, CraniUS Therapeuticsedale@craniusmed.com215-620-4482
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
a day ago
- Malaysian Reserve
Football Fans Have Reason to Celebrate this FIFA Club World Cup™
Hisense Offers Oman and Qatar Residents the Chance to Travel to the Champion Club's City DUBAI, UAE, June 2, 2025 /PRNewswire/ — Hisense, a global leader in consumer electronics and home appliances and official sponsor of the FIFA Club World Cup 2025™, is marking the upcoming tournament with an exclusive offer for consumers in Qatar and Oman. In celebration of this year's Club World Cup, Hisense is giving fans living in the two countries the opportunity to turn their support into rewards as part of the brand's 'Own the Moment' initiative. From 23 May to 13 July 2025, shoppers who purchase selected Hisense products from authorised retail stores, brand shops, or official e-commerce platforms in Qatar and Oman will be entered into a raffle draw. Two MEGA prize winners will each receive a travel voucher to visit the home country of the club that wins the FIFA Club World Cup™, experiencing the spirit of the tournament up close.* The FIFA Club World Cup 2025™ will bring together the world's best clubs in a celebration of sporting excellence, uniting football fans from around the world in the energy of the game. Hisense's 'Own the Moment' campaign invites fans to embrace all aspects of the tournament viewing experience, whether at home or in the stands, through its cutting-edge technology. As an official tournament partner, Hisense will provide groundbreaking technology solutions, including video assistant referee (VAR) screens and broadcast technology support, showcasing its commitment to innovation and excellence in sport. 'Football is a shared language and a source of deep connection for millions,' said Jason Ou, President of Hisense Middle East and Africa. 'Through this campaign, we are giving our fans the chance to have lasting memories and experience the thrills of the tournament long beyond the matches.' *Offer valid in Qatar and Oman during the campaign period (Qatar: 1 June–13 July, Oman: 23 May–13 July 2025). Eligible customers who purchase select Hisense products (min. QAR 1,799 / OMR 185) can enter the raffle to win. One entry per qualifying purchase, max five entries per customer. Prizes are non-transferable, non-refundable, and travel is valid until 20 December 2025. About Hisense Hisense, founded in 1969, is a globally recognised leader in home appliances and consumer electronics with operations in over 160 countries, specialising in delivering high-quality multimedia products, home appliances, and intelligent IT solutions. According to Omdia, Hisense ranks No. 2 worldwide in total TV shipments (2022-2024) and No. 1 globally in the 100-inch and over TV segment (2023-2024). As the first official partner of the FIFA Club World Cup 2025™, Hisense is committed to global sports partnerships as a way to connect with audiences worldwide. With 34 industrial parks, 30 R&D centres and 66 overseas companies, Hisense continues to lead the industry with a diverse range of products. With regional headquarters in Dubai, UAE, and 5 offices across the MENA region, Hisense ensures efficient manufacturing, innovation, and distribution, to meet the evolving needs of consumers in the market. Stay updated with all the latest developments on the website: For media inquiries, please contact hisense@ Photo:
Malaysian Reserve
2 days ago
- Malaysian Reserve
Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough
Conference call and webcast to be held at 8:30 a.m. ET NEW HAVEN, Conn., June 1, 2025 /PRNewswire/ — Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced a conference call and live webcast taking place tomorrow, Monday, June 2nd, 2025, at 8:30 a.m. ET, to share topline results from the Phase 2b CORAL trial of Haduvio in patients with IPF chronic cough. Conference Call/WebcastThe Company will host a conference call and webcast to review the topline results. The live webcast, including audio and presentation slides, will be accessible at the time of the meeting and can be accessed here. To participate in the live conference call by phone, please dial (877) 870 4263 (domestic) or (412) 317 0790 (international) and ask to join the Trevi Therapeutics call. No code is necessary for access. An archived replay of the webcast will also be available for 30 days on the Company's website following the event. About Idiopathic Pulmonary Fibrosis (IPF) Chronic CoughChronic cough is a highly prevalent condition in patients with IPF, impacting up to 85% of the IPF population. There are ~140,000 patients in the U.S. with IPF. The impact of chronic cough is significant with patients coughing up to 1,500 times per day. This consistent cough and any associated damage may lead to worsening disease, a higher risk of progression, death, or need for lung transplant. Chronic cough also often leads to a decline in patients' social, physical, and psychological quality of life. There are no approved therapies for the treatment of chronic cough in patients with IPF and current off-label treatment options provide minimal benefit to patients. About Trevi Therapeutics, Inc. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials of patients with IPF chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency. Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority. For more information, visit and follow Trevi on X (formerly Twitter) and LinkedIn. Investor ContactJonathan CarlsonTrevi Therapeutics, Inc.(203) 654 3286carlsonj@ Media ContactRosalia Scampoli914-815-1465rscampoli@
Malaysian Reserve
3 days ago
- Malaysian Reserve
Argo Corporation Reports First Quarter 2025 Financial Results
TORONTO, May 30, 2025 /CNW/ – Argo Corporation (TSXV: ARGH), (OTCQX: ARGHF) ('Argo' or the 'Company'), a leader in next-generation transit solutions, announced its financial results for the quarter ended March 31, 2025 ('Q1 2025'). All figures are in Canadian dollars unless otherwise noted. Municipal Deployments Argo has made significant progress in the commercialization of its Smart Routing™ technology. The Company's first municipal deployment in the town of Bradford West Gwillimbury launched in the second quarter of 2025, as previously announced by the Company. Argo also announced its landmark $10.9 million 12-month pilot with the City of Brampton in the second quarter of 2025, anticipated to launch later this year. While revenue from these agreements was not reflected in Q1 2025 results, the Company expects to begin recognizing related revenues in the second and third quarters of 2025. Argo continues to advance a robust pipeline of municipal opportunities, positioning the Company for continued growth. Research & Development of Smart Routing™ Transit System In Q1 2025, the Company continued its investment in research and development to enhance its proprietary Smart Routing™ hardware and AI-powered software ecosystem, including vertical integration hardware onboard its Argo X1 electric vehicles. This end-to-end platform combines real-time routing software, electric vehicles and full-service operations to deliver dynamic, on-demand transit services. FoodsUp Inc. The company held a 47.851% interest in FoodsUp Inc. ('FoodsUp') as of March 31, 2025. FoodsUp is one of Canada's leading restaurant supply platforms, with annual revenues of $108 million in fiscal 2024. As previously disclosed, the Company made significant progress towards the divestment of this ownership interest in Q1 2025: Sale of Shares: The Company received approximately $2.5 million in proceeds from the sale of an aggregate of 5,855 subordinate-voting shares of FoodsUp Inc. Option Agreements: The Company entered into two option agreements (collectively, the 'Option Agreements') granting the holders thereof the irrevocable option to purchase up to a total of 45,932 subordinate-voting shares of FoodsUp. If the transactions contemplated by the Option Agreements are fully exercised, the Company has the potential to receive gross proceeds of between $21.6 million and $30.2 million. The Company's ability to complete the transactions provided for in the Option Agreements remain subject to any required approvals, including final approval of the TSX Venture Exchange and approval of the shareholders of the Company. In addition, in the second quarter of 2025, the Company announced that its board of directors declared a special stock dividend (the 'Stock Dividend') intended to provide its legacy shareholders with their proportionate stake in the net proceeds realized upon the eventual sale by the Company of its ownership interest in FoodsUp. Pursuant to the Stock Dividend, all of the Company's common shareholders of record on August 13, 2025 (the 'Record Date') will be entitled to receive, one Preferred Share, Series A of Argo for each common share of Argo held on the Record Date. The payment date for the Stock Dividend is August 20, 2025. Additional details regarding the Stock Dividend can be found in the Company's press release dated May 21, 2025. For detailed information, please refer to Argo's condensed interim consolidated financial statements for the three months ended March 31, 2025, and 2024 ('Q1 2025 Financial Statements') and its management's discussion and analysis of financial condition and results of operations for the three months ended March 31, 2025, and 2024 (the 'Q1 2025 MD&A'), filed on SEDAR+ at The following table provides a summary of Argo's financial results for the three months ended March 31, 2025 and 2024: For the three months ended March 31 2025 2024 REVENUE $512,172 $219,585 Cost of revenue $115,987 $12,956 General and administration 2,570,907 966,946 Operational support 663,431 239,207 Research and development 224,492 49,174 Sales and marketing 10,648 34,802 Provision for trade and other receivables – – Amortization & depreciation 18,490 34,746 Depreciation 25,989 7,584 Total operating expenses 3,629,944 1,345,415 OPERATING LOSS ($3,117,772) ($1,125,830) OTHER INCOME (EXPENSES) Foreign exchange gain/ (loss) (14,791) (40,069) Interest expenses (427,312) (228,616) Interest income – 897 Loss on termination (996,968) – Write-off of accounts payable settlements – 98,202 Fair value gain (loss) on investments 2,726,221 – Gain on sale of investment 105,864 – Share of loss of an associate – (1,083,495) Net income/ (loss) from continuing operations ($1,724,758) ($2,378,911) Discontinued Operations Net gain/(loss) from discontinued operations, net of tax 497 (489,791) Gain from derecognition, net of tax – 1,341,770 NET GAIN (LOSS) ($1,724,261) ($1,526,932) Cumulative translation adjustment (342) 78,655 Cumulative translation adjustment for discontinued operations – (252,661) NET PROFIT (LOSS) AND COMPREHENSIVE PROFIT (LOSS) ($1,724,603) ($1,700,938) (Loss) Profit per share (Loss) income per share from continuing operations – Basic and diluted ($0.01) ($0.02) Income (loss) per share from derecognition and discontinued operations – Basic and diluted $0.00 $0.01 Weighted average shares outstanding – Basic and diluted 138,683,002 132,944,615 All figures rounded to the nearest dollar. Prepared in accordance with IFRS. About Argo Argo delivers the world's first fully vertically integrated transit system, combining Argo X1 electric vehicles, Smart Routing™ technology, and comprehensive operational management in a single end-to-end solution. By integrating every aspect of the transit experience, Argo enables municipalities to augment traditional fixed-route services to dynamically optimized on-demand service while maintaining standard public transit pricing. The company launched Argo School in September 2024 and began its first municipal deployment in Bradford West Gwillimbury in early 2025. Learn more at Praveen Arichandran, CEOArgo Corporation(800) 575-7051 Forward-Looking Information This news release includes certain forward-looking statements as well as management's objectives, strategies, beliefs and intentions. Forward-looking statements are frequently identified by such words as 'may', 'will', 'plan', 'expect', 'anticipate,' 'estimate,' and 'intend,' and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. The forward- looking information set out in this news release relates to future events or our future performance and includes, without limitation, statements concerning the recognition of revenue in future quarters, the future growth of the Company, the completion of the completion of the exercise of the options granted pursuant to the Option Agreements by the holders thereof, Argo's ability to obtain all necessary approvals in respect of the Option Agreements and the Stock Dividend, and Argo's intention with respect to the Stock Dividend. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, as described in more detail in the Company's securities filings available at Actual events or results may differ materially from those projected in the forward-looking statements, and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law. See 'Cautionary Note Regarding Forward-Looking Information', 'Financial Risk Management Objectives And Policies' and 'Other Business Risks and Uncertainties' in the Company's Q1 2025 Financial Statements and its Q1 2025 MD&A for a discussion of the uncertainties, risks and assumptions associated with these statements and other risks. Readers are urged to consider the uncertainties, risks, and assumptions carefully when evaluating forward-looking information and are cautioned not to place undue reliance on such information. We have no intention and undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities legislation and regulatory requirements. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
